Afucosylated antibody services are services involving the engineering of monoclonal antibodies to be devoid of the core fucose residue of the N-glycan on the Fc portion of an antibody. Afucosylated monoclonal antibodies have been shown to exhibit enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). Afucosylation has been utilized in cancer immunotherapy as afucosylation of the antibody Fc region leads to a higher affinity for binding to FcγRIIIa of immune effector cells such as NK cells and macrophages. Afucosylation does not seem to negatively impact binding to antigen or activation of complement-mediated responses.
The FDA-approved glycoengineering technique of afucosylation boosts ADCC activity by removing the steric block from the core fucose at Asn297, which strengthens FcγRIIIa binding. IgG1 has one N-linked glycosylation site at the asparagine 297 residue in the Cdomain that is attached to a biantennary, complex type oligosaccharide with modifications of galactose, sialic acid and/or fucose. The Fc region's glycosylation status, however, affects Fcγ receptor binding without impacting either antigen recognition or circulation time. Because core fucose is attached to the inner GlcNAc creating steric hindrance, flexibility of Fc is limited allowing only for suboptimal interaction with FcγRIIIa, found on NK cells. Decreased affinity of Fc binding to FcγRIIIa causes greater binding to the inhibitory FcγRIIb. Removal of core fucose relieves restrictions allowing for tighter binding to FcγRIIIa leading to stronger activating signals. Antibodies without core fucose have shown greater activity against lymphomas and leukemias with higher overall response rates due to potent NK cell activity. Increased ADCC mediated cellular killing makes afucosylation ideal for indications where potent cellular cytotoxicity is desired over complement dependent cytotoxicity. With clinical data emerging that supports increased FcγRIIIa binding translating to clinical benefit, high-ADCC antibodies are in high demand. Afucosylation is now standard for therapeutic antibodies being developed for oncology indications targeting both hematologic malignancies as well as solid tumors.
Schematic representation of IgG antibodies and the interaction with DENV1,5
Afucosylation of therapeutic antibodies has been shown to improve ADCC. Mechanistically, removing core fucose residues alleviates steric hindrance that prevents "productive" interactions between antibody Fc domains and FcγRIIIa, expressed on natural killer cells. By relieving spatial constraints of intermolecular glycans, afucosylation enables higher avidity binding due to closer approach of antibody complexes. Though there is no direct change to the amino acid sequence by afucosylation of antibodies, subtle changes in Cdomain conformation allows easier rearrangement for secondary site docking. Increased binding avidity allows for increased signaling within effector cells leading to increased degranulation.
Table 1 Comparative Features of Fucosylated versus Afucosylated Antibodies
| Feature | Fucosylated IgG1 | Afucosylated IgG1 | Functional Consequence |
| Core fucose status | Present | Absent | Determines spatial accessibility of glycan interface |
| FcγRIIIa binding | Low affinity | High affinity | Modulates immune synapse stability |
| ADCC potency | Moderate | Enhanced | Affects target cell elimination efficiency |
| Conformational flexibility | Restricted | Increased | Influences receptor cross-linking capability |
Fucose is a negative regulator of FcγRIIIa binding because it sterically hinders close contact between key glycans and the FcγRIIIa necessary for strong immune complex formation. When fucose is attached to innermost N-acetylglucosamine of the Fc glycan, it sterically excludes the Asn162 glycan of FcγRIIIa from approaching too close to the Fc glycan. Consequently, intimate carbohydrate–carbohydrate hydrogen bonds between Fc and FcγRIIIa cannot form. Instead, small modifications need to occur in FcγRIIIa's binding site to account for the fucose. These subtle adjustments decrease binding enthalpy, permitting immune complexes to dissociate before the generation of an effector cell response.
Increased effector activity has been shown to result from increased stability of Fc–receptor binding once carbohydrate residues exposed by lack of core fucose permit cross-linking. Removal of core fucose from FcγRIIIa allows the N-glycan at Asn162 to make extensive interactions with the Fc glycan that effectively creates a second site of interaction in addition to classical protein–protein contacts. The glycan link rigidifies the complex resulting in lower entropy and extended duration of receptor occupancy. In turn, this leads to extended signaling via immunoreceptor tyrosine-based activation motifs in NK cells, allowing increased degranulation and greater killing of antibody-opsonized cells.
Afucosylated antibodies have been shown to be more effective clinically in treating leukemias and lymphomas, as well as solid tumors because they increase the ADCC against tumor cells. Anti-CD20 antibodies defucosylated versions have received approval for clinical use and have shown more effective depletion of B cells, specifically when targeting lymphoma. Defucosylated antibodies were also shown to have higher response rates in the clinic than their fucosylated versions. These types of antibodies can be especially beneficial for tumor cells that express low levels of antigens or in individuals with unfavorable FcγRIIIA allotypes. These approved antibodies provide clinical proof that afucosylation can lead to potent antitumor effects with tolerable toxicity.
We have developed a platform technology for the manufacturing of core fucose-free antibodies. This technology combines genome editing and process development to efficiently produce afucosylated antibodies that have potent effector functions. The platform allows you to knockout any gene in the host cells, optimize upstream processing, and modify glycans in the downstream process. Our genome editing technology allows you to perform cell engineering while preserving cell viability and productivity and knock out specific unwanted glycosylation in the host. Platform spans from monoclonal antibody discovery through expression and manufacturing. This allows for candidate discovery using transient expression technology and seamlessly move into stable cell line development for material production.
Using CRISPR/Cas technology, FUT8 can be knocked out (KO) to generate cell lines that are unable to add core fucose to antibodies. Guide RNAs (gRNAs) targeting exons which encode for the enzymatic active site of α-1,6 fucosyltransferase can be used to introduce a double stranded break by Cas9 nuclease. After repairing the DNA, loss-of-function alleles are introduced which knockout FUT8 expression. Cells that have both alleles knocked out (biallelic) will continue to be FUT8-deficient through future generations since selection is not necessary to maintain the knockout. These cell lines can be used to express antibodies that lack core fucose on the Fc glycan. Cell lines with FUT8 knockout have the capability of continuous production of these antibodies. Cell lines that lack FUT8 have similar growth rates to their parent cell lines but have the benefit of producing a homogeneous antibody glycoform. Due to the knockout being genetic, the cells will be able to produce a consistent product over time. When at scale, cell lines can be used to produce antibodies for commercial use. Individual clones can be screened to determine which cell line has the desired characteristics. Properties such as cell growth can be compared between cell lines to determine the most productive clone. Because there are simple assays to determine if the cell clone is defucosylated or not, cell lines can be easily screened.
Approaches that globally target glycosylation have also been used to indirectly affect antibody fucosylation. Limiting availability of sugar substrates necessary for glycosylation through downregulation of enzymes required for the synthesis of GDP-Fucose, effectively limits the availability of donor substrate needed for fucosylation. Targeting upstream glycosylation machinery results in an upstream bottleneck of glycan processing and indirectly limits core fucosylation without directly targeting FUT8. Precisely regulating glycan synthesis requires balancing the expression of various glycosyltransferases that compete for substrate in the Golgi. Increasing expression of certain branch factors limits fucosyltransferase access to substrate through spatial competition. Competition among glycosylation enzymes can shift glycan synthesis towards structures less prone to core fucosylation while preserving glycan complexity.
Efforts are made to formulate the cell culture media in such a way that cells exhibit consistent defucosylation along with providing the cells with enough nutrients (carbohydrate source, trace minerals etc.) for the expression of high levels of antibodies without adding any sugar that the cell cannot metabolize (due to the knockout). Parameters like temperature, pH and oxygen levels also play a role in ensuring consistent glycosylation patterns. Changing these parameters slightly can influence enzyme localization within the Golgi complex, thus altering afucosylation. Culture conditions are tightly monitored and regulated to avoid any deviation that may reduce antibody production or influence glycosylation patterns. Development engineers work toward maintaining the glycosylation profiles seen on a small scale when manufacturing at larger scales. Parameters like mixing characteristics, shear sensitivity and oxygen transfer rates can influence glycosylation events at large scale since glycan processing might be influenced by these parameters.
Removal of fucose can also be achieved by remodeling strategies in vitro. Starting from standard material glycan remodeling approaches using glycosidases are highly versatile alternatives to produce afucosylated antibodies. Complete deglycosylation of antibodies can be achieved without denaturing the protein by cascades of enzymatic digestion first trimming heterogenous glycans, followed by the addition of defined non-fucosylated glycans by means of engineered glycosynthase mutants. Fast screening techniques have been developed to quickly assess the extent of remodeling and study the functionality of antibodies subjected to this process. Glycan structure changes during remodeling can be monitored by analytical methods, allowing for adjustment of reaction parameters such as enzyme concentrations, reaction time and buffer conditions. These methods also allow screening of lead candidates at an early stage if quick access to afucosylated proteins is desired before establishing a stable producer cell line.
Schematic representation of transglycosylation of palivizumab to generate homogeneous glycoforms2,5
Thorough characterization of afucosylated antibodies involves a series of analytical procedures aimed at confirming the removal of core fucose and determining the effectiveness of the modification. This includes analyzing the glycan structure, measuring affinity to its receptor, and assessing its activity in activating effector cells. Physicochemical properties are determined alongside biological activity to identify key quality parameters of afucosylated antibodies. Parameters such as glycoform distribution, consistency between production runs, and activity are evaluated to correlate the lack of fucose with increased antibody-dependent cell-mediated cytotoxicity.
Table 2 Dimensions of Afucosylated Antibody Characterization
| Characterization Domain | Primary Objective | Analytical Approach |
| Structural Analysis | Confirm absence of core fucose | Glycan profiling and mass spectrometry |
| Binding Assessment | Evaluate receptor interaction strength | Surface-based binding assays |
| Functional Verification | Validate immune cell activation | Cell-based cytotoxicity assays |
| Consistency Monitoring | Ensure batch uniformity | Comparative glycan analysis |
Orthogonal separation methods used to determine the structure of antibody glycans are typically coupled to mass spectrometry detection. Quantitative N-glycan analysis by LC-MS will identify and relatively quantify the glycans observed by accurate mass measurement and retention time. Using HILIC allows the chromatographic separation of structural isomers due to polarity. Charged glycans can be separated by capillary electrophoresis according to electrophoretic mobility. These orthogonal separation methods allow one to determine the distributions of glycans produced. Afucosylated and fucosylated glycans can be differentiated as well as the level of heterogeneity produced from recombinant antibodies.
FcγRIIIa binding assays measure the binding capacity of afucosylated Abs to the FcγR responsible for interaction with NK cells. Techniques such as surface plasmon resonance measure antibody binding kinetics as they associate and dissociate from FcγRIIIa in real time. This assay gives thermodynamic information about the interaction which can indicate greater avidity of afucosylated glycoforms. Biolayer interferometry (Octet) assays also measure affinity in a label-free manner using optical biosensors and allow high throughput screening. Flow cytometry techniques can measure binding affinity to FcγRIIIa on cell surfaces. This method leaves the receptor in its natural membrane-bound state on a cell, with its glycoproteins intact. Results from these assays have shown that the afucosylated variants of antibodies show increased stability in their interactions with FcγRIIIa.
Functional assays of ADCC involve directly measuring the ability of afucosylated antibodies to induce destruction of target cells by effector cells. NK cell based assays measure the activation of natural killer cells (primary or engineered) in the presence of target cells expressing antigen, usually by release of cytotoxic enzymes or reduction in viability of the target cells. Reporter gene assays use genetically engineered cell lines expressing FcγRIIIa receptors upstream of a reporter that produces a luminescent signal when induced (similar to a luciferase assay). Activation of the receptor by cross-linking triggers the signal. These functional cell-based assays serve to biologically confirm that glycoengineering increases ADCC potential. Using functional assays, potency can be defined and standardized to help ensure reproducibility of the functional activity of manufactured antibodies.
Batch-to-batch consistency looks at the consistency of afucosylation levels produced from batch to batch. There is naturally heterogeneity present in glycans expressed on antibodies. Analyzing glycan heterogeneity and batch-to-batch consistency allows one to confirm that each manufacturing campaign of afucosylated antibodies will result in homogeneous glycosylation. Lot-to-lot variation can occur due to natural differences in cell metabolism or drift in process conditions resulting in changes to degree of fucosylation, galactosylation at various branches, and sialylation. The range of glycoforms expressed and their relative abundance can be tracked within a batch and between different production lots to ensure that the glycosylation profile meets specifications. Identifying root causes of heterogeneity allows one to exert control over the production process to reduce heterogeneity. Ideally each batch produced will have similar structural characteristics and biological activity. Maintaining a consistent glycosylation profile is important to ensure that high ADCC activity is consistent between batches.
Batch-to-batch consistency looks at the consistency of afucosylation levels produced from batch to batch. There is naturally heterogeneity present in glycans expressed on antibodies. Analyzing glycan heterogeneity and batch-to-batch consistency allows one to confirm that each manufacturing campaign of afucosylated antibodies will result in homogeneous glycosylation. Lot-to-lot variation can occur due to natural differences in cell metabolism or drift in process conditions resulting in changes to degree of fucosylation, galactosylation at various branches, and sialylation. The range of glycoforms expressed and their relative abundance can be tracked within a batch and between different production lots to ensure that the glycosylation profile meets specifications. Identifying root causes of heterogeneity allows one to exert control over the production process to reduce heterogeneity. Ideally each batch produced will have similar structural characteristics and biological activity. Maintaining a consistent glycosylation profile is important to ensure that high ADCC activity is consistent between batches.
Applications for afucosylated antibodies with increased ADC are mostly focused on cancer drugs for blood cancers and tumors. Cancerous cells that are derived from B-cells, like certain lymphomas and leukemias, have shown increased sensitivity to stronger ADC since they are more exposed to NK cells in the bloodstream. Cancer treatments for solid tumors have targeted receptor tyrosine kinases as well as growth factor receptors. This applies to tumor cells with low levels of antigens on the surface as well. This is desirable so that a higher percentage of cancer cells can be killed with the least amount of dosage possible.
Antibodies containing afucosylated Fc regions can also be used to construct bispecific antibodies. Bispecific antibodies can target two tumor antigens at once, improving specificity and limiting off-target binding through avidity, while recruiting immune effector cells to destroy malignant cells. Because afucosylation prevents loss of binding ability due to increased structural complexity, bispecific antibodies containing afucosylated Fc regions can bind to two different antigens on tumor cells and still recruit NK cells and macrophages with high affinity. Bispecific antibodies may have applications in overcoming intratumoral heterogeneity and therapy resistance seen with single agent treatment.
Afucosylated antibody drug conjugates (Afucosylated ADCs) offer a dual mechanism of action to target tumor cells: targeted delivery of a cytotoxic payload along with potent antibody-dependent cell-mediated cytotoxicity. Improved Fc region interaction with effector cells allows for greater proximity of the conjugated cytotoxic drug to these cells. This closeness can lead to cooperation between cytotoxic mechanisms and ADCC. An advantage of ADCs is targeting heterogeneous tumors that may be resistant to either cytotoxic payloads or antibody therapy alone. Glycoengineered afucosylation improves the potency of antibody targeting moieties even when conjugated to cytotoxic drugs that could otherwise alter Fc receptor binding.
Afucosylated next-generation immuno-oncology antibodies exploit this modification for mechanisms of action that work indirectly to kill tumor cells such as blocking immune checkpoints. Antibodies are being designed to target immune checkpoint receptors found on immunosuppressive cells. These cells are then depleted from tumors through afucosylated-mediated ADCC. Targeting these immunosuppressive cells allow for a pro-inflammatory milieu within the tumor that can activate an adaptive immune response.
Manufacturing consistency challenges In moving from research production methods into larger scale biomanufacturing processes for commercial development there are many possible process related variables that can induce heterogeneity in glycosylation as well as impacting batch-to-batch consistency. As afucosylated antibodies have modifications from their natural counterparts, there are additional safety concerns that need to be addressed. Balancing maximal activity of immune effector functions with safety can be challenging. With any modification away from a naturally occurring molecule there is a concern for immunogenicity that will need to be fully evaluated and documented for regulatory filings. Overall, these challenges are interconnected and can be addressed through a focus on genetic stability, thorough analytical characterization, and risk assessment.
Table 2 Overview of Development Challenges and Strategic Responses
| Challenge Domain | Core Issue | Strategic Approach |
| Manufacturing consistency | Glycan heterogeneity at scale | Process analytical technology integration |
| Safety management | Balancing efficacy and toxicity | Mechanism-based dosing optimization |
| Immunogenicity prevention | Novel epitope exposure | Comprehensive antigenicity assessment |
| Regulatory alignment | Complex characterization requirements | Early agency engagement and validation |
One of the main technical hurdles to overcome for consistent afucosylation at different scales of production is linked to variability in cell metabolism and process parameters. As processes are scaled up, small changes in nutrient concentrations, dissolved oxygen or shear stress can affect enzyme activity in the Golgi resulting in production of mixed glycans with some remaining fucose residues. Additionally, the host cell line used may be genetically unstable and mutate back to a form that can add fucose. Process development should include clone testing to ensure stable producer cell lines are used. Control strategies should be developed to track critical quality parameters throughout production. Optimization of media components will help ensure precursor metabolites for glycosylation are consistently present. In addition, operating conditions should be tightly controlled to minimize unexpected variation.
Effective induction of ADCC should be carefully balanced with safety. Agonistic activity of Fc receptors may result in deleterious outcomes, including cytokine storm or unwanted tissue damage mediated by ADCC against antigens expressed on healthy tissues. Determination of optimal effector function activity for safety should be guided by mechanism informed models and supported by toxicology studies. This should be achieved by dosing to determine the MBED of antigen-specific activity and biomarkers of Concern (cytokine release) in parallel with clinical dose escalation. The specificity for individual Fc receptors should also be modulated to selectively activate vs block activating Fc receptors.
Changes in glycosylation can lead to possible immunogenicity issues caused by either recognition of new glycans, or removal of glycans creating new epitopes. For example, if there is a lack of core fucose on glycans there may be protein epitopes which become exposed and generate a humoral or cellular immune response. Also, if new glycans are introduced through cell engineering they could potentially be identified by the immune system as foreign. Possible solutions to decrease this risk include extensive immunogenicity testing using in silico prediction, in vitro anti-drug antibody assays, and clinical monitoring. Using cell lines that do not introduce foreign sugars helps decrease the chance of immunogenicity.
Glycoengineered antibodies must meet all standard regulatory requirements for safety and efficacy. Additionally, agencies must be provided with detailed characterization data showing that changes in glycosylation (i.e. removal of fucose) do not alter the safety and efficacy of the product. Stability of structure and function must be demonstrated along with absence of off-target effects. Adequate comparability data must be shown that demonstrates the modification does not impact the known safety and efficacy of the drug product. Meeting these expectations will require careful quality control throughout production, validated analytical approaches to glycan analysis, and comprehensive documentation of glycan structure-function relationships. Close collaboration with regulatory agencies throughout antibody development can assist in defining characterization needs for future biosimilar and glycoengineered products.
Developing afucosylated antibodies with enhanced ADCC requires more than simply disrupting FUT8 or modifying Fc glycans. It demands deep expertise in glycoengineering biology, robust analytical characterization, scalable process development, and regulatory foresight. Our integrated platform combines scientific rigor with translational experience to help you accelerate high-potency antibody programs from early discovery through IND-enabling stages.
Our team brings extensive experience in antibody glycosylation biology, Fc engineering, and effector function modulation. We understand the structural and mechanistic basis by which core fucose removal enhances FcγRIIIa binding and amplifies ADCC activity.
Our scientific approach ensures that afucosylation is not only achieved but precisely controlled and functionally validated, supporting both potency enhancement and product consistency.
Afucosylated antibody development requires coordinated efforts across cell line engineering, process optimization, analytics, and regulatory documentation. We provide seamless, end-to-end support across all critical stages:
By integrating glycoengineering with development and regulatory strategy, we help reduce technical risk, streamline timelines, and support smoother transitions toward clinical manufacturing.
Every antibody molecule presents unique structural and functional requirements. We tailor our afucosylated antibody development services to align with your specific therapeutic goals, target indication, and development stage.
Our customized approach ensures that glycoengineering decisions are data-driven and aligned with your molecule’s intended clinical performance.
We recognize that glycoengineering strategies can represent a significant competitive advantage. All projects are managed under strict confidentiality frameworks, with scalable solutions designed to support future clinical and commercial manufacturing.
Our goal is not only to enhance ADCC through afucosylation, but to deliver a development-ready solution that withstands regulatory scrutiny and supports long-term product success.
References
